Literature DB >> 24203525

The role of cirrhosis in the etiology of hepatocellular carcinoma.

Michael C Kew1.   

Abstract

Abundant evidence supports the belief of a causal relationship between cirrhosis and hepatocellular carcinoma, but one that differs between high- and low-incidence regions of the tumor. In high-incidence regions, the cirrhosis is of the macronodular variety, is typically asymptomatic, and is caused predominantly by chronic hepatitis B virus infection, whereas in low-incidence regions, the cirrhosis, although usually macronodular, may be micronodular, is commonly symptomatic and of long-standing, and is caused by chronic hepatitis C virus infection, alcohol abuse over many years, the metabolic syndrome, or hereditary hemochromatosis. In a minority of patients, hepatocellular carcinoma develops in the absence of cirrhosis, supporting a direct hepatocarcinogenic effect of some of the causal agents. Cirrhosis is the major risk factor for tumor formation in patients with chronic hepatitis C virus infection. This virus does not integrate into cellular DNA, and malignant transformation results from increased liver cell turnover induced by recurring injury and regeneration of cells in the context of persisting inflammation, oxidative DNA damage, fibrosis, cirrhosis, and changes induced by the virus at a DNA level that have yet to be fully defined. Hepatitis B virus causes malignant transformation by both direct and indirect routes. The direct route results, in part, from integration of the viral DNA into host cellular DNA; transcriptional activation of host growth regulatory genes by hepatitis B virus-encoded proteins; and effects on apoptosis, cell signaling, and DNA repair. The direct route may share some similarities with that of hepatitis C virus infection. The metabolic syndrome may cause malignant transformation by production of oxidative stress and the induction of a variety of mutations, including some in the p53 gene.

Entities:  

Mesh:

Year:  2014        PMID: 24203525     DOI: 10.1007/s12029-013-9556-9

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  121 in total

1.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease.

Authors:  Zobair M Younossi; Ancha Baranova; Katharine Ziegler; Luca Del Giacco; Karen Schlauch; Timothy L Born; Hazem Elariny; Francesco Gorreta; Amy VanMeter; Abraham Younoszai; Janus P Ong; Zachary Goodman; Vikas Chandhoke
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

2.  Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis.

Authors:  P J Johnson; N Krasner; B Portmann; A L Eddleston; R Williams
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

3.  Hepatitis C virus E2 protein promotes human hepatoma cell proliferation through the MAPK/ERK signaling pathway via cellular receptors.

Authors:  Lan-Juan Zhao; Lu Wang; Hao Ren; Jie Cao; Li Li; Jin-Shan Ke; Zhong-Tian Qi
Journal:  Exp Cell Res       Date:  2005-04-15       Impact factor: 3.905

Review 4.  Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis.

Authors:  K Matsubara; T Tokino
Journal:  Mol Biol Med       Date:  1990-06

Review 5.  The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology.

Authors:  Stephen Caldwell; Sang H Park
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

6.  Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma.

Authors:  C Brechot; C Pourcel; A Louise; B Rain; P Tiollais
Journal:  Nature       Date:  1980-07-31       Impact factor: 49.962

7.  Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

Authors:  F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

8.  Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C.

Authors:  Sabina Mahmood; Miwa Kawanaka; Ayumi Kamei; Akiyoshi Izumi; Keiichi Nakata; Gouichi Niiyama; Hideji Ikeda; Shinichi Hanano; Mitsuhiko Suehiro; Kazumi Togawa; Gotaro Yamada
Journal:  Antioxid Redox Signal       Date:  2004-02       Impact factor: 8.401

Review 9.  Hepatic fibrosis: can we treat it clinically?

Authors:  K Das; Abhijit Chowdhury
Journal:  Trop Gastroenterol       Date:  2008 Apr-Jun

10.  Hepatocellular carcinoma in the non-cirrhotic liver: a comparison with that complicating cirrhosis.

Authors:  W M Melia; M L Wilkinson; B C Portmann; P J Johnson; R Williams
Journal:  Q J Med       Date:  1984
View more
  6 in total

1.  Inhibition of diethylnitrosamine-initiated alcohol-promoted hepatic inflammation and precancerous lesions by flavonoid luteolin is associated with increased sirtuin 1 activity in mice.

Authors:  Bruna Paola Murino Rafacho; Camilla Peach Stice; Chun Liu; Andrew S Greenberg; Lynne M Ausman; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

2.  Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes.

Authors:  Seh-Hoon Oh; Marzena Swiderska-Syn; Mark L Jewell; Richard T Premont; Anna Mae Diehl
Journal:  J Hepatol       Date:  2018-05-23       Impact factor: 25.083

Review 3.  Hepatocellular carcinoma: epidemiology and risk factors.

Authors:  Michael C Kew
Journal:  J Hepatocell Carcinoma       Date:  2014-08-13

4.  Effects of recombinant human adenovirus-p53 on the regression of hepatic fibrosis.

Authors:  Yehong Liu; Puye Yang; Na Chen; Shumei Lin; Min Liu
Journal:  Int J Mol Med       Date:  2016-08-26       Impact factor: 4.101

5.  Liver stiffness measurement predicted liver-related events and all-cause mortality: A systematic review and nonlinear dose-response meta-analysis.

Authors:  Junna Wang; Jiajun Li; Quan Zhou; Dandan Zhang; Qiu Bi; Yulin Wu; Wenxiang Huang
Journal:  Hepatol Commun       Date:  2018-02-13

Review 6.  Ambiguous roles of innate lymphoid cells in chronic development of liver diseases.

Authors:  Yue Shen; Jing Li; Si-Qi Wang; Wei Jiang
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.